Dynavax Technologies Stock Price - DVAX

0.53 (10.95%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Dynavax Technologies Corp DVAX NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.10 -2.02% 4.84 4.75 4.93 4.85 4.94 20:00:00
Bid Price Ask Price Spread Spread % News
5.20 5.40 0.20 3.7% - 1
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
11,243 2,560,947 $ 4.86 $ 12,443,025 5,068,654 1.80 - 7.43
Last Trade Time Type Quantity Stock Price Currency
19:59:58 formt 400 $ 5.37 USD

Dynavax Technologies Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 446.17M 92.18M 90.21M $ 35.22M $ - -2.18 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Dynavax Technologies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DVAX Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week6.116.244.625.206,957,026-1.27-20.79%
1 Month4.047.433.555.356,356,5840.8019.8%
3 Months4.347.431.804.513,433,9420.5011.52%
6 Months5.667.431.804.842,310,704-0.82-14.49%
1 Year5.757.431.804.571,871,133-0.91-15.83%
3 Years5.7024.451.8010.711,650,671-0.86-15.09%
5 Years22.0532.491.8011.481,390,072-17.21-78.05%

Dynavax Technologies Description

Dynavax Technologies Corp is a clinical-stage biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. It's current product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Dynavax operates in the business segment the discovery and development of biopharmaceutical products. Its Toll-like Receptor Immune Modulation Platform technology play a vital role in innate immunity and subsequent adaptive immunity. Signaling through these receptors is triggered by the binding of a variety of pathogen-associated molecules and is essential to the generation of innate immunity.

Your Recent History
Dynavax Te..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.